AEterna Zentaris (AEterna Zentaris) Equity-to-Asset : 0.49 (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is AEterna Zentaris Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. AEterna Zentaris's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $18.20 Mil. AEterna Zentaris's Total Assets for the quarter that ended in Dec. 2023 was $37.02 Mil. Therefore, AEterna Zentaris's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.49.

The historical rank and industry rank for AEterna Zentaris's Equity-to-Asset or its related term are showing as below:

AEZS' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.13 Med: 0.33 Max: 0.66
Current: 0.49

During the past 13 years, the highest Equity to Asset Ratio of AEterna Zentaris was 0.66. The lowest was -0.13. And the median was 0.33.

AEZS's Equity-to-Asset is ranked worse than
64.96% of 1564 companies
in the Biotechnology industry
Industry Median: 0.66 vs AEZS: 0.49

AEterna Zentaris Equity-to-Asset Historical Data

The historical data trend for AEterna Zentaris's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris Equity-to-Asset Chart

AEterna Zentaris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Equity-to-Asset

Get a 7-Day Free Trial

-0.12

0.36

0.66

0.64

0.49

AEterna Zentaris Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Equity-to-Asset	Get a 7-Day Free Trial															0.64	0.61	0.63	0.62	0.49

Competitive Comparison of AEterna Zentaris's Equity-to-Asset

For the Biotechnology subindustry, AEterna Zentaris's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AEterna Zentaris's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AEterna Zentaris's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where AEterna Zentaris's Equity-to-Asset falls into.

AEterna Zentaris Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

AEterna Zentaris's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	18.196	/	37.016
	=	0.49

AEterna Zentaris's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	18.196	/	37.016
	=	0.49

AEterna Zentaris (NAS:AEZS) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

AEterna Zentaris Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

AEterna Zentaris (AEterna Zentaris) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (NAS:AEZS) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

ET8:Germany ET8:Germany AEZS:Canada

Address

222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7

Website

https://www.zentaris.com

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.